Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.
Robert J FoxHeinz WiendlChristian WolfNicola De StefanoJohann SellnerViktoriia GrybKonrad RejdakPlamen S BozhinovDaniel VittHella KohlhofJason SlizgiMatej OndrusValentina SciaccaAndreas R Muehlernull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
ClinicalTrials.gov (NCT03846219) and EudraCT (2018-001896-19).